Asthma is a relatively widespread respiratory condition characterized primarily by chronic inflammation of the bronchi. The correct medical term is bronchial asthma. It’s estimated that approximately 5 to 10% of the world’s population suffers from some form of asthma. The severity varies considerably, with milder forms often going undiagnosed.
📑 Inhaltsverzeichnis
Acute attacks are classically treated with asthma sprays based on beta-2 agonists. Particularly in the 19th century, long before cannabis prohibition, cannabis cigarettes were a widely used remedy for asthma. Cannabis can provide noticeable relief in the bronchi due to its anti-inflammatory properties.
Now new research findings suggest that the body’s own cannabinoid anandamide could represent a new treatment option. Furthermore, there appears to be a direct connection between an imbalance in the endocannabinoid system and the development of asthma.
Anandamide Indirectly Expands the Bronchi
A research team recently concluded that anandamide could open an entirely new treatment pathway for asthma. Through observations in mice, researchers demonstrated that anandamide indirectly leads to relaxation of the smooth respiratory muscles and thus expansion of the bronchi. This is precisely the mechanism that conventional asthma sprays produce, relieving acute breathing difficulties in this way.
It’s important to understand that anandamide works indirectly here. The relief effect is not triggered directly by action on cannabinoid receptors, but rather by the action of certain metabolic breakdown products. Anandamide is broken down in the body by the enzyme FAAH. During this breakdown process, arachidonic acid is produced among other compounds. The specific action of arachidonic acid on the smooth respiratory muscles is the actual cause of the observed bronchial expansion.
Study Check: The Endocannabinoid System in Asthma
Current research reveals three critical breakthroughs in understanding respiratory diseases:
- The Anandamide Effect: Anandamide expands the bronchi indirectly via its breakdown products (arachidonic acid). Unlike conventional sprays, this produces no receptor tolerance – meaning the effect remains stable even with frequent use.
- Speed of Inhalation: In animal studies, inhaled anandamide showed similarly rapid effects on respiratory muscles as modern beta-2 agonists (emergency sprays).
- The Role of OEA: While anandamide provides protection, overactivity of the lipid oleoylethanolamide (OEA) can promote airway inflammation. An imbalance in this system appears to be a fundamental cause of chronic asthma.
Conclusion: Targeted regulation of the endocannabinoid system offers a promising approach for future asthma therapies with minimal side effects.
Researchers believe this mechanism of action could represent an entirely new therapeutic option for humans in the future. Compared to current emergency medications using beta-2 agonists, this newly discovered endocannabinoid system pathway has one decisive advantage: there is no desensitization of respiratory muscles and no tolerance development at the involved receptors. This is a known problem with conventional asthma sprays during frequent use that can lead to dangerous complications during acute symptoms. The described anandamide metabolism responsible for bronchial expansion also occurs surprisingly quickly. Observations in mice showed that inhaled anandamide produces measurable effects similarly fast as conventional beta-2 agonists.
Possible Cannabis Alternative to THC
In principle, medical cannabis proves to be a possible therapeutic option for asthma – explained in detail in the article How Cannabis Helps with Asthma. The plant contains numerous anti-inflammatory cannabinoids, particularly THC, which contributes to relaxation and expansion of airways. For this reason, medical cannabis was also one of the main components of the asthma cigarettes known in earlier centuries.
However, inhaling cannabis with asthma is also a double-edged sword. While on one hand the bronchi relax and tissue inflammation is relieved, the classic inhalation method with irritated airways should always be approached with caution. At the same time, some asthmatic patients react paradoxically to cannabis inhalation: THC doesn’t widen their bronchi but instead triggers a bronchial spasm – precisely the opposite effect desired during an attack. This individual problem could potentially be addressed in the future with anandamide, since its mechanism of action and biochemical signaling pathway are completely different from THC found in the cannabis plant.
The Endocannabinoid System is Involved in Asthma Development
Researchers increasingly believe that a chronic deficiency of the cannabinoid anandamide could be one of the fundamental causes of asthma development. The presence of adequate anandamide in the bronchi can also reduce the general occurrence of irritation and inflammation through adequate muscle tone. A deficiency in anandamide has already been linked in various studies to several other serious disease conditions – learn more in the article on clinical endocannabinoid deficiency.
Conversely, overactivity of another lipid in the extended endocannabinoid system – oleoylethanolamide – can actually promote asthma development. The endocannabinoid system is an extremely complex construct consisting of many finely coordinated regulatory mechanisms. Countless body functions are controlled and kept in balance directly or indirectly through the endocannabinoid system.
As early as 2021, a Korean study impressively demonstrated that in asthma patients compared to healthy individuals, oleoylethanolamide exhibits excessively strong effects in certain areas of eosinophils. These are a specific type of white blood cell that are part of the immune system. Some metabolic products of these eosinophils have a direct connection to asthma development. Researchers believe that increased oleoylethanolamide activity in the endocannabinoid system stimulates the production of pro-inflammatory cytokines in precisely this cell type, which ultimately play a major role in the development of chronic respiratory diseases such as asthma or COPD.
FAQ: Endocannabinoid System and Asthma
What is Anandamide and How Does It Work for Asthma?
Anandamide is an endogenous cannabinoid that indirectly expands the bronchi via its breakdown products (arachidonic acid). Unlike conventional beta-2 agonists found in asthma sprays, this process causes no desensitization or tolerance development.
Can an Imbalance in the Endocannabinoid System Cause Asthma?
Current research suggests that chronic anandamide deficiency as well as overactivity of oleoylethanolamide (OEA) can contribute to asthma development and chronicity. The endocannabinoid system regulates important inflammation and muscle functions in the airways.
Is Cannabis Use Beneficial for Asthma?
THC can expand the bronchi in some asthmatics while triggering paradoxical bronchial spasms in others. Anandamide offers a potential alternative through its completely different mechanism of action. Medical consultation is advisable in any case.
Sources and Further Reading:
- Study on Anandamide and Airways (2023):
Endocannabinoid signaling in the lung (PMC10105667)
- Research on FAAH Inhibitors and Bronchi:
Fatty acid amide hydrolase and airway reactivity (PubMed)
- Korean Study on Oleoylethanolamide (2021):
Role of OEA in eosinophilic inflammation (Nature)
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
